

Press Release

Ono Venture Investment Relocates to Cambridge, Massachusetts — Accelerating Open Innovation and Maximizing Strategic Returns —

Osaka, Japan, October 1, 2026 — Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”) today announced that its corporate venture capital arm, Ono Venture Investment, Inc. (“OVI”), has relocated its operating base from South San Francisco, California, to Cambridge, Massachusetts, where it is now located within the office of ONO PHARMA USA, INC. (“OPUS”), Ono’s U.S. subsidiary.

Rationale for the Relocation to Cambridge, Massachusetts

Since its establishment in 2020, OVI has made strategic investments in biotechnology companies, primarily in North America, to gain access to innovative science, technologies, and drug discovery opportunities. In recent years, many of OVI’s portfolio companies have been based in the Greater Boston area, which has further strengthened its importance as one of the world’s leading life sciences innovation hubs.

Through this relocation to Cambridge, OVI will deepen its engagement with portfolio companies and startups, while continuing to maximize strategic returns.

About Ono Venture Investment, Inc. (OVI)

Established: May 2020

Location: 1 Main Street, Suite 1050, Cambridge, MA 02142, USA

Purpose: Strategic investments to gain access to innovative drug discovery technologies and pipelines

Investment Focus: Primarily seed- to Series A-stage biotechnology companies

Fund Size: US\$200 million

Contact:

Ono Pharmaceutical Co., Ltd.

Corporate Communications

public_relations@ono-pharma.com